Dr. Karsten Fischer, CEO

Dr. Karsten Fischer is MEMO’s CEO and a senior executive in the life science field. Prior to joining MEMO, he was a partner of BioMedPartners AG, a renowned European Venture Capitalist in the field of biotechnology, medical technology and diagnostics, where he did several investments into successful companies. Previously, Dr. Fischer has been working for WestLB in the healthcare and chemicals sector where he was heading the equity capital markets team realizing large primary market transactions and the strategic analysis working on debt, M&A, and equity transactions. He started his career with Deutsche Venture Capital, an affiliate of Deutsche Bank, investing into bio- and medical technology companies. He then consulted large cap pharmaceutical companies with McKinsey&Company on sales and marketing strategies before he went to Sanofi Aventis being responsible for Sales Force and Marketing Excellence. He has a biochemistry and economics background and holds a Ph.D. in infection biology (MPI Infection Biology and Colorado State University, with distinction).

Dr. Christoph Esslinger, CSO, Board Member

Christoph Esslinger is MEMO’s CSO, scientific founder and a pioneer of the discovery of therapeutic antibody candidates directly from human donors for immunotherapy of Alzheimer’s Disease and cancer. Prior to founding MEMO he held senior positions at CT Atlantic AG, Neurimmune AG and in academia.

Christoph Esslinger holds a diploma in Technical Biology from University of Stuttgart and a PhD in Molecular Immunology from the Ludwig Institute for Cancer Research, Lausanne Branch and University of Lausanne.

Dr. Dragan Gabulovski, Business Development & Strategy, Board Member

Dr. Dragan Grabulovski is an advisor in pharmaceutical biotechnology at Grabulovski Consulting Services (CH). He was previously chief scientific officer and co-founder of Covagen AG, a Swiss biotech company acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. As Covagen’s CSO, he was responsible for developing and overseeing the execution of the overall strategy for research and development. He was a main inventor of the Fynomer technology, established a portfolio of novel bispecific FynomAb product candidates and managed the internal and collaboration pipeline. As a member of Covagen’s executive management team, Dr. Grabulovski was instrumental in Covagen’s trade sale to Johnson & Johnson, and in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2014 with the participation of renowned investors such as GIMV, Edmond de Rothschild Investment Partners, Novartis Venture Fund and other prestigious funds. Dr. Grabulovski received his master’s degree in pharmaceutical sciences and Doctor of Sciences from ETH Zurich (CH). He is a co-author of several peer-reviewed articles, reviews, book chapters, poster abstracts, patent applications and granted patents.


Dr. Simone Schmitt, Head Antibody Development

Simone Schmitt joined MEMO from Delenex Therapeutics AG, a biotech company focused on the development of single chain antibodies for the treatment of inflammatory diseases. One of her major achievements during her tenure at Delenex was the discovery and engineering of single chain antibody DLX2681 with an affinity in the sub-picomolar range. She is a co-inventor on two patent applications that issued from her work.

Dr. Schmitt is an experienced protein biochemist and molecular biologist. She did her PhD with Prof. Dr. Dr. Walter Neupert at LMU, Munich and postdoctoral work with Prof. Dr. Kai Johnsson at EPFL, Lausanne.